Wouter Meuleman, Ph.D.

team-member-details

Wouter Meuleman, Ph.D.

Partner

Wouter was part of the founding team at Illumina Ventures and brings more than 20 years of experience in life sciences tools development and genomics to the fund. Previously, he was director of Corporate Development at Illumina, where he led investments including Desktop Genetics (acquired by Celixir in 2018). Wouter also held senior roles in Research and Development (R&D) and Product Development at Illumina, and was instrumental in the development of sequencing platforms, the sourcing and evaluation of new technology opportunities, and competitive benchmarking.

An electrochemist by training, Wouter made his debut in life sciences in 2003 as first hire for Oxford University spin-out Oxamer, a company founded by Lasker-award winner professor Sir Edwin Southern, where he contributed to the development of a benchtop DNA microarray fabrication platform. Following the company’s merger with Oxford Gene Technology (later acquired by Sysmex), he continued working alongside Prof. Southern, leading R&D on single cell gene expression analysis and novel applications for DNA microarrays.

Wouter obtained a joint Bachelor and Master of Science (magna cum laude) in Chemistry from Ghent University, Belgium; a Ph.D. in Chemical Engineering from Newcastle University, UK; a Master of Business Administration from the University of Cambridge’s Judge Business School; and is a Kauffman Fellow.

Portfolio Involvement

  • Arbor Biotechnologies
  • Delfi Diagnostics
  • Fluent Biosciences
  • Precede Biosciences
  • RedShiftBio
  • Ribometrix
  • Sherlock Biosciences
  • Tagomics
View Full Team